DIACEUTICS PLC

Board/Management Information • Sep 21, 2023

National Storage Mechanism | Additional information

RNS Number : 2604N

Diaceutics PLC

21 September 2023

Diaceutics PLC - Directorate Changes

Graham Paterson appointed as an independent Non-Executive Director

Charles Hindson retiring as a Non-Executive Director

Belfast and London, 21 September 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, today announces the appointment of Graham Paterson as an independent Non-Executive Director of Diaceutics PLC effective 1 October 2023. The Company also announces the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023.

Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc. He has held senior executive roles in a number of companies including TopQ Software Ltd and SL Capital Partners.

Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC.

Deborah Davis, Diaceutics' Non-Executive Chair, commented: "I would like to thank Charles for his hard work, dedication and much valued counsel during the past four years and wish him well in his future endeavours.

I warmly welcome Graham to the board of Diaceutics, his extensive leadership and board experience will contribute significantly to our work and support our growth as we become the primary commercialisation partner for pharma and biotech companies launching precision medicines."

Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

The following information is disclosed in relation to Graham Douglas Paterson, aged 52:

Current Directorships	Past Directorships (previous 5 years)
Baillie Gifford US Growth Trust Plc Invesco Perpetual UK Smaller Companies Investment Trust Plc Mobeus Income and Growth 4 VCT Plc Datactics Ltd Substantive Research Ltd The Wemyss Development Company Ltd GDP 1 Ltd	The IDco Ltd Octopus VCT 4 Plc Berry Starquest Limited

Graham Paterson does not hold any ordinary shares or share options in the Company.

Save for the information disclosed above, there is no other information to be disclosed under Schedule 2(g) of the AIM Rules.

Enquiries:

Diaceutics PLC	Tel: +44 (0)28 9040 6500
Peter Keeling, Chief Executive Officer Ryan Keeling, Chief Innovation Officer Nick Roberts, Chief Financial Officer	investorrelations@diaceutics.com
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Nick Harland Kate Hanshaw
Alma PR	Tel: +44 (0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Matthew Young
Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostic Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOALBMJTMTJTBJJ